Skip to search formSkip to main contentSkip to account menu
Final version of 2009 AJCC melanoma staging and classification.
TLDR
Revised melanoma staging system has been made that reflect the improved understanding of this disease and will be formally incorporated into the seventh edition of the AJCC Cancer Staging Manual and implemented by early 2010.
View on PubMed
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
TLDR
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
View on PubMed
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.
TLDR
This revision of the staging system for cutaneous melanoma will become official with publication of the sixth edition of the AJCC Cancer Staging Manual in the year 2002.
View on PubMed
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
TLDR
The proposed tumor-node-metastases categories and stage groupings for cutaneous melanoma patients were validated and incorporated into the AJCC melanoma staging as described in the companion publication.
View on PubMed
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
TLDR
IFN alpha-2b is the first agent to show a significant benefit in relapse-free and overall survival of high-risk melanoma patients in a randomized controlled trial.
View on PubMed
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Answer questions and earn CME/CNE
View on Wiley
Genomic Classification of Cutaneous Melanoma
View on Elsevier
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.
TLDR
Serum-free generation of alphaDC1 allows, for the first time, the clinical application of DCs that combine the key three features important for their efficacy as anticancer vaccines.
View on PubMed
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
TLDR
The results of the intergroup E1690 trial demonstrate an RFS benefit of IFNalpha2b that is dose-dependent and significant for HDI by Cox multivariable analysis.
View on PubMed
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
TLDR
These findings support the use of Tim-3–Tim-3L blockade together with PD-1–PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction in patients with advanced melanoma.
View PDF
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License